PLUS

HEADLINES TREATMENT REGIMENS FROM THE ADVISORY BOARD PUBLISHERS ALLIANCE TOOLS MULTIMEDIA CME

FEATURES


Viewpoints

CLEOPATRA Reveals New Treatment Option for HER2+ Breast Cancer Patients

CLEOPATRA Reveals New Treatment Option for HER2+ Breast Cancer Patients

Addition of pertuzumab to traztuzumab + docetaxel added almost 16 months to overall survival compared to those who didn't receive pertuzumab.

Does Regulatory Bureaucracy Drive Disparities in Cancer Drug Access Around the World?

Does Regulatory Bureaucracy Drive Disparities in Cancer Drug Access Around the World?

Regional disparities in cancer drug access have complex causes, including bureaucratic differences and variation in health care spending.

Feature Articles

Risks and Benefits of Phase 1 Clinical Trial Participation

Risks and Benefits of Phase 1 Clinical Trial Participation

[Cancer Control] Research derived from phase 1 clinical trials can be vital to the development of new treatments. There are long-lasting positive and negative impacts on those patients who choose to participate in phase 1 clinical trials, but participant safety is a priority.

Treating advanced melanoma: Current insights and opportunities

Treating advanced melanoma: Current insights and opportunities

[Cancer Management and Research] Although thin melanomas have an excellent prognosis after sufficient surgical treatment, melanoma disease in advanced stages still proves to be a therapeutic challenge. In the last several years, new therapeutic strategies have emerged.

Human Papilloma Virus and Squamous Cell Carcinoma of the Anus

Human Papilloma Virus and Squamous Cell Carcinoma of the Anus

[Clin Med Insights Oncol] HPV is a risk factor for anal intraepithelial neoplasia (AIN). The etiology, anatomy, pathogenesis, management of squamous cell carcinoma (SCC) are discussed.

Slideshows

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed follicular non-Hodgkin lymphoma (FL).

Table of Contents

Slide 3: Indication, Dosage, ...

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide ...

From the Advisory Board

What to Consider When It Comes to Surgery in Elderly Patients With Cancer

What to Consider When It Comes to Surgery in Elderly Patients With Cancer

Dr. Jeffrey Farma provides his insight on treating the elderly patient population in the surgical oncology setting.

CME

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs